Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Subcutaneously Injected PD-L1 Antibody Envafolimab (KN035) Obtained Its Second Orphan Drug Designation From The U.S. FDA

prnasiaJune 30, 2021

Tag: Alphamab , Envafolimab , PD-L1 , ODD

PharmaSources Customer Service